SHPH

Shuttle

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 0

MACD Golden Cross

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About SHPH

Shuttle Pharmaceuticals Holdings, Inc.

A biotechnology company with a focus on radiation therapy

Industry

Biological Technology

Established Date

Invalid Date

Listing Date

08/31/2022

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.shuttlepharma.com

Security Type

Common stock

Office address

401 Professional Drive, Suite 260, Gaithersburg, MD 20879

Business

Introduction

Shuttle Pharmaceuticals Holdings, Inc., was incorporated as a limited liability company in December 2012 and transformed into C Company Shuttle Pharmaceuticals, Inc. (" Shuttle ") in August 2016. In June 2018, Shuttle completed a share exchange with Shuttle Pharma Acquisition Corp., pursuant to which Shuttle Pharmaceuticals, Inc., became a subsidiary of Acquisition Corp., Acquisition Corp.'s name was subsequently changed to Shuttle Pharmaceuticals Holdings, Inc. The company is a clinical-stage pharmaceutical company that uses proprietary technology to develop new therapies aimed at curing cancer. The company's goal is to expand the benefits of cancer treatment through surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the most effective ways to treat cancer. The company is developing a range of products designed to address the limitations of current cancer therapies and expand to new applications of radiotherapy.

Company Financials

EPS

SHPH has released its 2023 Q3 earnings. EPS was reported at -0.11, versus the expected 0.00, missing expectations. The chart below visualizes how SHPH has performed over recent quarters, highlighting trends in earnings surprises.